Work

Department of Error

Year: 2026

Type: article

Abstract: Nauck MA, Tuttle KR, Tschöp MH, Blüher M. GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet 2026; 407: 892–908—In this Review, Matthias H Tschöp's affiliations should have included Ludwig-Maximilians-Universität München (LMU Munich), Munich, Germany. In the Declaration of interests section, statements have been corrected for Michael A Nauck, Matthias H Tschöp, and Matthias Blüher. The appendix has been corrected. These corrections have been made to the online version as of March 12, 2026.

Source: The Lancet

DOI: 10.1016/s0140-6736(26)00467-8

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $7,890

OpenAlex ID: W7135027283

FWCI:

Cites:

Cited by:

Related to: